Personal Genome Diagnostics
2809 Boston St, Suite 503
54 articles with Personal Genome Diagnostics
Personal Genome Diagnostics Announces Medicare Coverage of PGDx elio™ tissue complete Assay for Patients with Advanced Cancer
Reimbursement Now Available for Comprehensive Test that can be Performed in Labs Across the Country, Expanding Local Access to Personalized Cancer Care BALTIMORE--( BUSINESS WIRE )-- Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, announced today that the CMS Molecular Diagnostics Program (MolDX) has issued a local coverage determination (LCD) for the FDA-cleared PGDx elio™ tissue complete assay. The MolDX coverage determination
Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, appointed Megan Bailey as Chief Executive Officer (CEO), promoted from Chief Commercial Officer (CCO).
Industry veteran to drive global commercialization of cancer genomics product line
Personal Genome Diagnostics and Eisai Co., Ltd. Collaborate to Develop Comprehensive Liquid Biopsy Biomarker Discovery Solution
Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, is partnering with Eisai Co., Ltd. to develop a comprehensive liquid biopsy biomarker discovery solution for oncology, to be used by Eisai researchers at their Tsukuba Research Laboratory.
Personal Genome Diagnostics and Mayo Clinic Enter Strategic Collaboration to Enhance Patient Care in Oncology
Technology optimization and clinical utility studies to enhance liquid biopsy and tissue-based genomic applications for cancer patients
Personal Genome Diagnostics Receives Investigational Device Exemption Approval from the FDA to Support Merck’s Precision Oncology Trial
Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for the use of the company’s elio™ tissue complete assay in a Merck trial of pembrolizumab-based combination therapy.
Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced that it has applied the CE mark to the PGDx elio™ tissue complete assay.
PGDx elio™ plasma resolve liquid biopsy panel brings a local, non-invasive, clinical Next-Generation Sequencing (NGS) solution to Europe
Personal Genome Diagnostics Welcomes New Members to Board of Directors, Bringing Proven, Industry-Leading Experience in Precision Medicine and Healthcare Policy
Two new additions deepen Board expertise and will be critical to driving the PGDx vision of empowering local, standardized Next Generation Sequencing, impacting cancer patients globally
Personal Genome Diagnostics and PathGroup Enter Co-Development Agreement to Accelerate the Availability of Comprehensive Genomic Profiling with TMB
Partnership brings together innovative genomic technology with pathology expertise and real-world insights, enabling greater testing solutions that can inform critical treatment decisions for patients
International Clinical Trial Utilizes Personal Genome Diagnostics’ Liquid Biopsy Assay to Enroll Patients based on POLE/POLD1 status as a Predictor of Response to Immunotherapy
Study examines PGDx technology as an innovative, non-invasive approach with the potential to reduce need for tumor biopsies
Machine Learning Approach by Personal Genome Diagnostics Outperforms Existing Mutation Detection Methods According to Study in Science Translational Medicine
Peer-reviewed research using PGDx software demonstrates importance of high-quality somatic mutation detection in clinical next-generation sequencing
Personal Genome Diagnostics’ PGDx elio™ Plasma Resolve Receives Breakthrough Device Designation from FDA
Personal Genome Diagnostics Inc. today announced that PGDx elio™ plasma resolve has received Breakthrough Device designation from The Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA).
Personal Genome Diagnostics' TMB Analysis Used in Groundbreaking NEJM Study Showing Promising Checkpoint Inhibitor Efficacy in Early Stage Lung Cancer
Personal Genome Diagnostics Inc. reported that its whole exome analysis platform contributed to an important new study published in the New England Journal of Medicine (NEJM) showing promising efficacy for a leading checkpoint inhibitor in early stage lung cancer.
Personal Genome Diagnostics Expands Its Tumor Mutational Burden (TMB) Patent Portfolio for Cancer Immunotherapy
Personal Genome Diagnostics Inc. (PGDx) today announced an agreement with Memorial Sloan Kettering Cancer Center (MSK) for developing, registering, and commercializing products and services that include tumor mutation burden (TMB) biomarker status.
PGDx is a leader in the development of tissue-based and liquid biopsy technologies and products for cancer genomics.
U.S. Dept. of Veterans Affairs Renews and Expands Cancer Testing Contract With Personal Genome Diagnostics
The contract includes PDGx's CancerSELECT 125 tissue and PlasmaSELECT64 liquid biopsy profiling panels.
Personal Genome Diagnostics Awarded Department Of Veterans Affairs Contract For Its PlasmaSELECT Liquid Biopsy Cancer Profiling Assay
Personal Genome Diagnostics Highlights Its Patent-Pending Microsatellite Instability Testing Technology As FDA Approves Keytruda For MSI Tumors
Personal Genome Diagnostics' Expanded PlasmaSELECT 64 Is First Liquid Biopsy Pan-Cancer Profiling Panel To Include MSI Analyses For Immuno-Oncology